We are live on ! Find out more
AMYT

Amryt Pharma

Delisted

AMYT was delisted on the 11th of April, 2023.

34 hedge funds and large institutions have $185M invested in Amryt Pharma in 2021 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 4

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

25% more capital inflows, than outflows

Capital inflows: $14.3M | Capital outflows: $11.4M

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

17% more funds holding

Funds holding: 29 → 34 (+5)

0.45% more ownership

Funds ownership: 23.42% → 23.88% (+0.45%)

Holders
34
Holders Change
+5
Holders Change %
+17.24%
% of All Funds
0.59%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.09%
New
11
Increased
9
Reduced
4
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

AMYT Hedge Fund Activity: Q2 2021 in Review

34 of the 5,771 institutional investors tracked by Wall St. Rank reported a position in Amryt Pharma (AMYT) for Q2 2021, worth a combined $185M — down 11% from $209M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new AMYT positions and 6 closed out — a net gain of 5 holders — while 9 added to existing stakes and 4 trimmed.

The largest buyer was Aquilo Capital Management, adding an estimated $4.22M. The largest seller was Highbridge Capital Management, cutting an estimated $4.21M.

  • 34 institutional investors held Amryt Pharma (AMYT) as of Q2 2021, up from 29 in Q1 2021.
  • Funds reported $185M of Amryt Pharma stock for Q2 2021, down 11% quarter-over-quarter.
  • 11 funds opened new Amryt Pharma positions in Q2 2021 and 6 closed out, a net change of +5 holders.
  • The largest Amryt Pharma buyer in Q2 2021 was Aquilo Capital Management, an estimated $4.22M added.
  • The largest Amryt Pharma seller in Q2 2021 was Highbridge Capital Management, an estimated $4.21M sold.

Based on aggregated 13F filings for Q2 2021.